AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Article Link
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Research Article

Efficiency against multidrug resistance by co-delivery of doxorubicin and curcumin with a legumain-sensitive nanocarrier

Sen Lin1,2,3( ), Peiling Xie1, Mengmeng Luo1, Qing Li2,3, Ling Li1, Jinzhao Zhang1, Qinxiang Zheng1, Hao Chen1,3, Kaihui Nan1,3( )
School of Ophthalmology & Optometry and Eye HospitalWenzhou Medical UniversityWenzhou325027China
Wenzhou Institute of Biomaterials and EngineeringChinese Academy of ScienceWenzhou325000China
School of Biomedical and EngineeringWenzhou Medical UniversityWenzhou325027China
Show Author Information

Abstract

Multidrug resistance proteins (MDRPs), which are implicated in the mediation of multidrug resistance in tumors, represent the main obstacle to successful chemotherapy. As curcumin (Cur) exerts inhibitory effects on both the expression and function of MDRPs, a nanocarrier for the co-delivery of Cur and doxorubicin (DOX) was prepared to overcome MDR tumors through their synergistic effects. Owing to the overexpression of legumain in tumors, the release profile of DOX from this nanocarrier was designed to be legumain modulated, which was achieved by bridging DOX to a basic material (chitosan) with a legumain-sensitive peptide. Compared with nanoparticles that only contain DOX, the coadministration of DOX and Cur significantly inhibited multidrug resistance (P < 0.05) in a multidrug-resistant cancer cell model (MCF-7/ADR cell line), with cytotoxicity to normal cells (L929 cell line). Such inhibition could be ascribed to the increased DOX accumulation in the MCF-7/ADR nucleus. The co-delivery system exhibited good anticancer effects through prolonged circulation time, improved tumor-targeting efficiency, elevation of the tumor inhibition activity, and the suppression of MDRP expression. These data revealed the enormous potential of this co-delivery system for cancer therapy, especially in the later stages where multidrug resistance may develop.

Graphical Abstract

Electronic Supplementary Material

Download File(s)
12274_2017_1928_MOESM1_ESM.pdf (2.3 MB)

References

【1】
【1】
 
 
Nano Research
Pages 3619-3635

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Lin S, Xie P, Luo M, et al. Efficiency against multidrug resistance by co-delivery of doxorubicin and curcumin with a legumain-sensitive nanocarrier. Nano Research, 2018, 11(7): 3619-3635. https://doi.org/10.1007/s12274-017-1928-1

1462

Views

33

Crossref

N/A

Web of Science

34

Scopus

5

CSCD

Received: 29 August 2017
Revised: 16 November 2017
Accepted: 19 November 2017
Published: 02 August 2018
© Tsinghua University Press and Springer-Verlag GmbH Germany, part of Springer Nature 2017